Lisata Therapeutics announces research license with Catalent

Lisata Therapeutics (LSTA) announced that the Company has entered into a research license with Catalent to evaluate, in a preclinical setting, the efficacy of Lisata’s iRGD cyclic peptide product candidate, certepetide, as a payload used in the context of Catalent’s SMARTag antibody-drug conjugate dual-payload technology platform for the treatment of difficult-to-treat-diseases, including advanced solid tumors. Under the terms of the agreement, Catalent will assume full responsibility for all research and development expenses and Lisata will provide consulting support. Further, Lisata will receive an upfront payment with the possibility of future considerations contingent upon the results of the preclinical evaluation.